Editorial: [18F]Fluorodeoxyglucose positron emission tomography in the management of lymphomas

Clinical Lymphoma and Myeloma

Volumn 8, Issue 5, 2008, Pages 273-276

  Kostakoglu, Lale ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT;

ADVANCED CANCER; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG MEGADOSE; DRUG UPTAKE; EDITORIAL; FALSE POSITIVE RESULT; FOLLICULAR LYMPHOMA; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMA; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TREATMENT PLANNING; TREATMENT RESPONSE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; INSTRUMENTATION; METHODOLOGY; NOTE; SCINTISCANNING; TIME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; TIME FACTORS;

EID: 58149350313     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2008.n.037     Document Type: Editorial

References (40)

1. Schaefer NG, Hany TF, Taverna C, et al. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging-do we need contrast-enhanced CT? Radiology 2004; 232:823-9.
2. Tatsumi M, Cohade C, Nakamoto Y, et al. Direct comparison of FDG PET and CT findings in patients with lymphoma: initial experience. Radiology 2005; 237:1038-45.
3. Isasi CR, Lu P, Blaufox MD. A metaanalysis of 18F-2-deoxy-2-fluoro-D- glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer 2005; 104:1066-74.
4. Rini JN, Leonidas JC, Tomas MB, et al. 18F-FDG PET versus CT for evaluating the spleen during initial staging of lymphoma. J Nucl Med 2003; 44:1072-4.
5. Buchmann I, Reinhardt M, Elsner K, et al. 2-(fluorine-18)fluoro-2-deoxy- D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer 2001; 91:889-99.
6. Rodríguez-Vigil B, Gómez-León N, Pinilla I, et al. PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT. J Nucl Med 2006; 47:1643-8.
7. Moog F, Bangerter M, Kotzerke J, et al. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. Blood 1998; 16:603-9.
8. Carr R, Barrington SF, Madan B, et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 1998; 91:3340-6.
9. Pakos EE, Fotopoulos AD, Ioannidis JP. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med 2005; 46:958-63.
10. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. N Engl J Med 1998; 339:1506-14.
11. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329:987-94.
12. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25:579-86.
13. Jerusalem G, Hustinx R, Beguin Y, et al. Evaluation of therapy for lymphoma. Semin Nucl Med 2005; 35:186-96.
14. Armitage JO, Weisenburger DD, Hutchins M, et al. Chemotherapy for diffuse large-cell lymphoma--rapidly responding patients have more durable remissions. J Clin Oncol 1986; 4:160-4.
15. Boyd DB, Coleman M, Papish SW, et al. COPBLAM III: infusional combination chemotherapy for diffuse large-cell lymphoma. J Clin Oncol 1988; 6:425-33.
16. Carde P, Koscielny S, Franklin J, et al. Early response to chemotherapy: a surrogate for final outcome of Hodgkin's disease patients that should influence initial treatment length and intensity? Ann Oncol 2002; 13 (suppl 1):86-91.
17. Vitolo U, Bertini M, Tarella C, et al. MACOP-B treatment for advanced stage diffuse large cell lymphomas: a multicenter Italian Study. Eur J Cancer Clin Oncol 1989; 25:1441-9.
18. Ginsberg SJ, Anderson JR, Gottlieb AJ, et al. A randomized trial of high-dose methotrexate versus standard-dose methotrexate following cyclophosphamide, doxorubicin (adriamycin), vincristine, and prednisone with or without bleomycin in the therapy of diffuse large cell lymphoma: preliminary report of Cancer and Leukemia Group B Study 7851. NCI Monogr 1987; 5:77-80.
19. Verdonck LF, van Putten WL, Hagenbeek A, et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 1995; 332:1045-51.
20. Juweid ME, Wiseman GA, Vose JM, et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 2005; 23:4652-61.
21. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25:579-86.
22. Hutchings M, Mikhaeel NG, Fields PA, et al. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 2005; 16:1160-8.
23. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006; 107:52-9.
24. Kostakoglu L, Goldsmith SJ, Leonard JP, et al. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer 2006; 107:2678-87.
25. Zinzani PL, Tani M, Fanti S, et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. Ann Oncol 2006; 17:1296-300.
26. Gallamini A, Rigacci L, Merli F, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 2006; 91:475-81.
27. Haioun C, Itti E, Rahmouni A, et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005; 106:1376-81.
28. Mikhaeel NG, Hutchings M, Fields PA, et al. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005; 16:1514-23.
29. Dupuis J, Gaulard P, Hemery F, et al. Respective prognostic values of germinal center phenotype and early (18)fluorodeoxyglucose-positron emission tomography scanning in previously untreated patients with diffuse large B-cell lymphoma. Haematologica 2007; 92:778-83.
30. Spaepen K, Stroobants S, Dupont P, et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 2002; 13:1356-63.
31. Strehl J, Mey U, Glasmacher A, et al. High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma: a meta-analysis. Haematologica 2003; 88:1304-15.
32. Wöhrer S, Jaeger U, Kletter K, et al. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading. Ann Oncol 2006; 17:780-4.
33. Karam M, Novak L, Cyriac J, et al. Role of fluorine-18 fluoro-deoxyglu-cose positron emission tomography scan in the evaluation and followup of patients with low-grade lymphomas. Cancer 2006; 107:175-83.
34. Schöder H, Noy A, Gönen M, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent aggressive non-Hodgkin's lymphoma. J Clin Oncol 2005; 23:4643-51.
35. Wirth A, Foo M, Seymour JF, et al. Impact of [18f ] fluorodeoxyglucose positron emission tomography on staging and management of earlystage follicular non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2008; 71:213-9.
36. Gribben JG. How I treat indolent lymphoma. Blood 2007; 109:4617-26.
37. Davies AJ. Clinical and molecular prognostic factors in follicular lymphoma. Curr Oncol Rep 2006; 8:359-67.
38. Bishu S, Quigley JM, Bishu SR, et al. Predictive value and diagnostic accuracy of F-18-fluoro-deoxy-glucose positron emission tomography treated grade 1 and 2 follicular lymphoma. Leuk Lymphoma 2007; 48:1548-55.
39. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25:571-8.
40. Lin C, Itti E, Haioun C, et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med 2007; 48:1626-32.